info@seagull-health.com

SeagullHealth

语言:

Homepage

Drugs

Enasidenib(Idhifa)

Names

恩西地平

Indicatons

Treatment of relapsed or refractory acute myeloid leukemia (AML) in adult patients with a confirmed IDH2 mutation.

Price:

Manufacturer:

Celgene

Dosage form:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Enasidenib(Idhifa) Instructions:Uses,Dosage, Side Effects

IDHIFA, with the generic name enasidenib, is an oral isocitrate dehydrogenase-2 (IDH2) enzyme inhibitor. It is formulated as film-coated tablets available in 50 mg and 100 mg strengths. The drug functions by targeting mutant IDH2 variants, leading to a reduction in the oncometabolite 2-hydroxyglutarate (2-HG) and promoting differentiation of myeloid cells. It is marketed by Bristol Myers Squibb Company.

Generic name

Enasidenib(Idhifa)

English name

Enasidenib

Alternative Names

恩西地平

Drug prices

Indications

IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved companion diagnostic test.

Therapeutic Target

Mutant Isocitrate Dehydrogenase 2 (IDH2) enzyme. IDHIFA specifically inhibits the mutant IDH2 variants R140Q, R172S, and R172K.

Active Ingredients

Enasidenib

Dosage Form

TABLET

Specifications

100mg * 30 tablets/box, 50mg * 30 tablets/box

Dosage and Administration

The recommended dosage is 100 mg taken orally once daily, with or without food.

Related Columns

Recommended articles

Enasidenib: Indications, Contraindications, and Dosage Guidelines for Special Populations

Enasidenib is a targeted agent against IDH2 mutations, used for the precise treatment of specific types of acute myeloid leukemia.I. Indications: Precision Targeting of IDH2 Mutations1. Sole Indicatio...

Complete Analysis of Enasidenib: Mechanism of Action, Drug Interactions, and Missed Dose Management

Enasidenib is an oral targeted therapy indicated for relapsed or refractory acute myeloid leukemia with IDH2 mutations.I. What is Enasidenib?1. Drug Profile(1) Enasidenib (brand name: IDHIFA) is an is...

Enasidenib: Dosage, Precautions, and Healthy Lifestyle Guidelines

Proper administration of enasidenib, avoidance of treatment risks, and adoption of a healthy lifestyle are critical to enhancing therapeutic efficacy and ensuring safety.1. Dosage and Administration1....

Enasidenib: Side Effects, Management Strategies, and Storage Guidelines

While treating IDH2-mutant acute myeloid leukemia (AML), enasidenib may cause various adverse reactions.I. Common Side Effects of Enasidenib1. Adverse Reactions with an Incidence Rate ≥ 20%Based on cl...

Enasidenib Dosage and Administration, Recommended Dose

Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH2 mutation.Enasideni...

Side Effects of Enasidenib

Enasidenib is a targeted therapeutic agent for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.Side Effects of EnasidenibGastroi...

Departments